CRYOSITE LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.85 AUD | -.--% |
|
+4.94% | +40.50% |
| Feb. 22 | Cryosite Limited Announces Board Changes | CI |
| Feb. 22 | Cryosite Limited Reports Earnings Results for the Half Year Ended December 31, 2023 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Cryosite Limited is engaged in providing outsourced clinical trials depot services. The Company manages the entire clinical trial supply chain from importation, receipt, specialized ambient, cold, frozen, and liquid nitrogen storage for temperature-sensitive products, distribution and reverse logistics management. Its segments include Clinical trials and biological services logistics and Cord Blood and tissue storage. The Clinical trials and biological services logistics segment provides specialist temperature-controlled storage, sourcing, labelling, status management, secondary packaging, schedule drug distribution, destruction, returns, biological services and cell gene therapies depot services. Cord Blood and tissue storage segment provides storage of cord blood and tissue samples. Its facilities are purpose-built to store a range of biological materials, including Cell Banks (MCB, WCB), Mesenchymal Stromal Cell (MSC) Therapies, Tumour-Infiltrating Lymphocyte Therapies and others.
Calendar
2024-08-22
- Q4 2024 Earnings Release (Projected)
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +40.50% | 26.94M | |
| -14.25% | 85.35B | |
| +14.46% | 81.95B | |
| +9.37% | 28.99B | |
| -11.40% | 16.98B | |
| -0.36% | 16.85B | |
| +0.22% | 15.35B | |
| +4.32% | 12.42B | |
| -2.34% | 11.88B | |
| +32.69% | 12.19B |
- Stock Market
- Equities
- CTE Stock
- News Cryosite Limited
- Cryosite Proposes Capital Return to Shareholders
